The recent launch of Eylea HD should lead to stronger sales growth for Regeneron next year. The company's hematology-oncology business could get a boost with a possible drug approval.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) American Society of Hematology 2023 Investor Conference Call December 14, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Re...

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Regeneron has a strong and diverse business with a couple of key assets in Eylea and Dupixent. The company also has dozens of trials ongoing that can further bolster its growth prospects.

Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinic...

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematolo...

Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.

Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ET Company Participants Dr. Len Schleifer - President and Chief Executive Officer Ryan ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Brook Jennings - Vice P...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ryan Crowe – Vice President-Investor Relations Leonard Schleifer – P...

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regenero...

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during t...

Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exceptions to this trend.